Exclusive Summary

• Inelastic first-line demand: Riluzole serves as the premier and universally utilized standard first-line oral therapy for ALS recommended by international guidelines, representing a highly rigid clinical necessity.
• Cost-effective rare disease portfolio booster: With innovator patents already expired, the sheer cost advantage of Chinese supply chains enables distributors to enrich their neurology and orphan drug portfolios to boost overall tender competitiveness.
• Stable revenue from life-long therapy: Given that ALS requires continuous life-long maintenance therapy (50mg twice daily), reliable high-quality manufacturing capacity offers overseas distributors sustainable and predictable long-tail commercial returns.